Alcami to Provide Manufacturing Services for Trevena’s Pain Management Injection
Alcami will provide services for Trevena’s OLINVYK (oliceridine) injection, an opioid approved for the management of acute pain severe enough to require an intravenous opioid analgesic in adults.
Alcami, a US-based contract development and manufacturing organization, announced on Aug. 26, 2020 that it will provide commercial manufacturing services for Trevena’s OLINVYK (oliceridine) injection, an opioid approved for the management of acute pain severe enough to require an intravenous opioid analgesic in adults.
“For Alcami, this is another example of our ability to partner with customers to provide comprehensive support services from development through commercial approval," said Walt Kaczmarek, CEO of Alcami, in the press release. "We congratulate Trevena on their novel product offering and important advancement in pain therapy and are proud to offer our expertise and support.”
Source: Alcami
VERAXA and Voyager to Create Combined Business for Advancing Pipeline of Next-Gen Cancer Therapies
April 23rd 2025The proposed business combination would create a publicly traded, clinical-stage biopharmaceutical company that will focus on developing a pipeline of next-generation cancer therapies.
